AU5319499A - Fatty acids to minimize cancer therapy side effects - Google Patents
Fatty acids to minimize cancer therapy side effectsInfo
- Publication number
- AU5319499A AU5319499A AU53194/99A AU5319499A AU5319499A AU 5319499 A AU5319499 A AU 5319499A AU 53194/99 A AU53194/99 A AU 53194/99A AU 5319499 A AU5319499 A AU 5319499A AU 5319499 A AU5319499 A AU 5319499A
- Authority
- AU
- Australia
- Prior art keywords
- fatty acids
- side effects
- cancer therapy
- therapy side
- minimize
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pediatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1999/016666 WO2001006983A2 (en) | 1999-07-22 | 1999-07-22 | Fatty acids to minimize cancer therapy side effects |
Publications (1)
Publication Number | Publication Date |
---|---|
AU5319499A true AU5319499A (en) | 2001-02-13 |
Family
ID=22273263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU53194/99A Abandoned AU5319499A (en) | 1999-07-22 | 1999-07-22 | Fatty acids to minimize cancer therapy side effects |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5319499A (en) |
WO (1) | WO2001006983A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ555163A (en) * | 2007-05-14 | 2010-05-28 | Fonterra Co Operative Group | Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments |
WO2009017802A1 (en) | 2007-08-01 | 2009-02-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Nitro-fattyacid modulation of type ii diabetes |
JP2011519373A (en) | 2008-05-01 | 2011-07-07 | コンプレクザ インコーポレイテッド | Vinyl-substituted fatty acids |
US8686038B2 (en) | 2008-06-19 | 2014-04-01 | The Univsersity of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
JP2013500966A (en) | 2009-07-31 | 2013-01-10 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Fatty acids as anti-inflammatory agents |
EP2483233A4 (en) | 2009-10-02 | 2013-08-14 | Complexa Inc | Heteroatom containing substituted fatty acids |
RU2549954C2 (en) * | 2009-10-22 | 2015-05-10 | Юниверсити Оф Саутерн Калифорния | Methods and nutritional formulations for increasing effectiveness and reducing side effects of cancer treatment |
WO2012141575A1 (en) * | 2011-04-14 | 2012-10-18 | N.V.Nutricia | Combination of epa, dpa and/or dha with a chemotherapeutic agent |
WO2013028501A1 (en) | 2011-08-19 | 2013-02-28 | The University Of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
KR102153143B1 (en) | 2012-01-06 | 2020-09-08 | 옴테라 파마슈티칼스, 인크. | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
KR20150028233A (en) | 2012-05-07 | 2015-03-13 | 옴테라 파마슈티칼스, 인크. | Compositions of statins and omega-3 fatty acids |
SI3865484T1 (en) | 2015-07-07 | 2024-05-31 | H. Lundbeck A/S | Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases |
AU2016331314A1 (en) | 2015-10-02 | 2018-05-17 | Complexa, Inc. | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
AU2017380092A1 (en) | 2016-12-23 | 2019-07-25 | Basf As | Omega-3 fatty acid composition for preventing and/or treating cachexia |
TWI823853B (en) * | 2017-06-13 | 2023-12-01 | 夏滉 | Use of a sensitizer for preparing a medicament |
BR112020024019A2 (en) | 2018-05-25 | 2021-02-23 | Imara Inc. | monohydrate and crystalline forms of 6 - [(3s, 4s) -4-methyl-1- (pyrimidin-2-ylmethyl) pyrrolidin-3-yl] -3-tetrahydropyran-4-yl-7h-imidazo [1, 5-a] pyrazin-8-one |
-
1999
- 1999-07-22 AU AU53194/99A patent/AU5319499A/en not_active Abandoned
- 1999-07-22 WO PCT/US1999/016666 patent/WO2001006983A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2001006983A2 (en) | 2001-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5319499A (en) | Fatty acids to minimize cancer therapy side effects | |
EP1212327B8 (en) | Pyrazolopyrimidines as therapeutic agents | |
AU3783599A (en) | Non-invasive methods to detect prostate cancer | |
NZ298712A (en) | Fatty acid acyl group conjugates as therapeutic compounds | |
AU3843200A (en) | Conjugated fatty acid esters | |
AU4735200A (en) | Vitamin directed dual targeting therapy | |
AU6078500A (en) | Combination therapy for conditions leading to bone loss | |
AU7882900A (en) | Hydrotherapy bed | |
AU6208100A (en) | Cancer treatment using angiopoietins targeted to aminophospholipids | |
AU7597000A (en) | Imaging of drug accumulation as a guide to antitumor therapy | |
AU2634101A (en) | Therapeutic preparations of highly unsaturated fatty acids | |
EP1242071A4 (en) | Use of parthenolide to inhibit cancer | |
AU3082401A (en) | Therapy of psoriasis | |
AU2451500A (en) | Therapeutic agents | |
AU8021000A (en) | Method for the direct esterification of sorbitol with fatty acids | |
AUPQ480399A0 (en) | Unsaturated fatty acids and their uses in therapy | |
AU7089800A (en) | 29 human cancer associated proteins | |
AU4443599A (en) | Therapeutic bed | |
AU2205801A (en) | Novel compounds of unsaturated fatty acids | |
SG93225A1 (en) | Higher unsaturated fatty acid composition | |
AU5552400A (en) | Treatment of cancer | |
AUPQ367699A0 (en) | Treatment of cancer | |
AU5973600A (en) | Therapeutic agents | |
AU7920198A (en) | Intratumoral administration of triphenylethylenes for the treatment of cancer | |
AU8139498A (en) | Preparation for topical application to the male sexual organ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |